Perlegen and Merck to Work on Whole-Genome Analysis
News Oct 05, 2005
Perlegen Sciences, Inc. has announced that it will assist Merck & Co., Inc. in conducting a high-density whole genome analysis of 1,000 individuals with important clinical characteristics.
Using Affymetrix GeneChip® technology including the GeneChip® Human Mapping 500K Array Set, Perlegen scientists will assay up to 675,000 genetic variations (also called single nucleotide polymorphisms or SNPs) in DNA samples provided by Merck.
Perlegen will utilize its high capacity SNP genotyping capability to rapidly generate extremely dense DNA variation data that can be integrated with other large datasets Merck has generated by molecular profiling clinically important tissue samples internally.
“We are pleased to work with Merck scientists in identifying DNA variations that may underlie biological mechanisms important to their drug discovery efforts,” Brad Margus, CEO of Perlegen.
“It was an honor to have been selected by Merck for this important project.”
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.